ChromaDex Co. (NASDAQ:CDXC) Short Interest Update

ChromaDex Co. (NASDAQ:CDXC) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,070,000 shares, an increase of 6.7% from the December 31st total of 1,940,000 shares. Approximately 4.3% of the company’s shares are short sold. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is currently 1.6 days.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CDXC shares. HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th. Roth Mkm boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 15th.

Insider Buying and Selling

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now owns 244,179 shares of the company’s stock, valued at $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.64% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ChromaDex

A number of institutional investors have recently added to or reduced their stakes in CDXC. Dimensional Fund Advisors LP bought a new stake in ChromaDex in the 2nd quarter worth about $88,000. Renaissance Technologies LLC grew its position in ChromaDex by 8.4% in the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock worth $1,136,000 after purchasing an additional 32,400 shares in the last quarter. Marshall Wace LLP bought a new position in shares of ChromaDex during the 2nd quarter valued at approximately $56,000. The Manufacturers Life Insurance Company bought a new position in shares of ChromaDex during the 2nd quarter valued at approximately $31,000. Finally, SG Americas Securities LLC bought a new position in shares of ChromaDex during the 3rd quarter valued at approximately $61,000. 15.41% of the stock is owned by institutional investors.

ChromaDex Price Performance

NASDAQ:CDXC opened at $5.49 on Tuesday. The firm has a 50-day moving average of $6.07 and a 200-day moving average of $4.69. The company has a market cap of $419.33 million, a PE ratio of 549.55 and a beta of 2.21. ChromaDex has a one year low of $1.46 and a one year high of $7.97.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.